MXPA04001848A - Asociacion de un antagonista del receptor cb1 y de un producto que activa la neurotransmision dopaminergica en el cerebro, las composiciones farmaceuticas que los contienen y su utilizacion para el tratamiento de la enfermedad de parkinson. - Google Patents
Asociacion de un antagonista del receptor cb1 y de un producto que activa la neurotransmision dopaminergica en el cerebro, las composiciones farmaceuticas que los contienen y su utilizacion para el tratamiento de la enfermedad de parkinson.Info
- Publication number
- MXPA04001848A MXPA04001848A MXPA04001848A MXPA04001848A MXPA04001848A MX PA04001848 A MXPA04001848 A MX PA04001848A MX PA04001848 A MXPA04001848 A MX PA04001848A MX PA04001848 A MXPA04001848 A MX PA04001848A MX PA04001848 A MXPA04001848 A MX PA04001848A
- Authority
- MX
- Mexico
- Prior art keywords
- brain
- composition
- treating parkinson
- receptor antagonist
- dopaminergic neurotransmission
- Prior art date
Links
- 208000018737 Parkinson disease Diseases 0.000 title abstract 2
- 230000003213 activating effect Effects 0.000 title abstract 2
- 210000004556 brain Anatomy 0.000 title abstract 2
- 230000015883 synaptic transmission, dopaminergic Effects 0.000 title abstract 2
- 229940123158 Cannabinoid CB1 receptor antagonist Drugs 0.000 title 1
- 239000003555 cannabinoid 1 receptor antagonist Substances 0.000 title 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 150000001539 azetidines Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0111201A FR2829027A1 (fr) | 2001-08-29 | 2001-08-29 | Association avec un antagoniste du recepteur cb1, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de parkinson |
| PCT/FR2002/002945 WO2003018060A1 (fr) | 2001-08-29 | 2002-08-28 | Composition pour le traitement de la maladie de parkinson contenant un antagoniste du recepteur cb1 et un produit qui active la neurotransmission dopaminergique dans le cerveau |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA04001848A true MXPA04001848A (es) | 2004-06-15 |
Family
ID=8866793
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA04001848A MXPA04001848A (es) | 2001-08-29 | 2002-08-28 | Asociacion de un antagonista del receptor cb1 y de un producto que activa la neurotransmision dopaminergica en el cerebro, las composiciones farmaceuticas que los contienen y su utilizacion para el tratamiento de la enfermedad de parkinson. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7105504B2 (https=) |
| EP (1) | EP1423146A1 (https=) |
| JP (1) | JP2005505539A (https=) |
| AR (1) | AR036303A1 (https=) |
| CA (1) | CA2458855A1 (https=) |
| FR (1) | FR2829027A1 (https=) |
| IL (1) | IL160558A0 (https=) |
| MX (1) | MXPA04001848A (https=) |
| WO (1) | WO2003018060A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7129239B2 (en) | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
| US7247628B2 (en) | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
| US7329658B2 (en) | 2003-02-06 | 2008-02-12 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
| US7176210B2 (en) | 2003-02-10 | 2007-02-13 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| AR044007A1 (es) * | 2003-04-11 | 2005-08-24 | Newron Pharmaceuticals Inc | Metodos para el tratamiento de la enfermedad de parkinson |
| US7141669B2 (en) | 2003-04-23 | 2006-11-28 | Pfizer Inc. | Cannabiniod receptor ligands and uses thereof |
| US7268133B2 (en) | 2003-04-23 | 2007-09-11 | Pfizer, Inc. Patent Department | Cannabinoid receptor ligands and uses thereof |
| US7145012B2 (en) | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| US7232823B2 (en) | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
| AU2004252109B2 (en) | 2003-06-11 | 2010-04-08 | Merck Sharp & Dohme Corp. | Substituted 3-alkyl and 3-alkenyl azetidine derivatives |
| EP1498123A1 (en) * | 2003-07-18 | 2005-01-19 | Aventis Pharma S.A. | Emulsifying systems containing azetidine derivatives |
| EP1498122A1 (en) * | 2003-07-18 | 2005-01-19 | Aventis Pharma S.A. | Semi-solid systems containing azetidine derivatives |
| EP1910290A2 (en) | 2005-06-30 | 2008-04-16 | Prosidion Limited | Gpcr agonists |
| US7906652B2 (en) | 2005-11-28 | 2011-03-15 | Merck Sharp & Dohme Corp. | Heterocycle-substituted 3-alkyl azetidine derivatives |
| RU2484815C2 (ru) * | 2006-05-31 | 2013-06-20 | Зольвай Фармасьютиклз Гмбх | Продолжительное 24-часовое введение в кишечник леводопа/карбидопа |
| CL2008000018A1 (es) | 2007-01-04 | 2008-08-01 | Prosidion Ltd | Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci |
| EA016507B1 (ru) | 2007-01-04 | 2012-05-30 | Прозидион Лимитед | Пиперидиновые агонисты gpcr |
| US20100048632A1 (en) | 2007-01-04 | 2010-02-25 | Matthew Colin Thor Fyfe | Piperidine GPCR Agonists |
| PE20081849A1 (es) | 2007-01-04 | 2009-01-26 | Prosidion Ltd | Derivados de piperidin-4-il-propoxi-benzamida como agonistas de gpcr |
| GB0700122D0 (en) | 2007-01-04 | 2007-02-14 | Prosidion Ltd | GPCR agonists |
| GB0720390D0 (en) | 2007-10-18 | 2007-11-28 | Prosidion Ltd | G-Protein coupled receptor agonists |
| GB0720389D0 (en) | 2007-10-18 | 2008-11-12 | Prosidion Ltd | G-Protein Coupled Receptor Agonists |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020177593A1 (en) * | 1998-09-30 | 2002-11-28 | Yuji Ishihara | Agents and crystals for improving excretory potency of urinary bladder |
| US6479479B2 (en) * | 2000-03-03 | 2002-11-12 | Aventis Pharma S.A. | Azetidine derivatives, their preparation and pharmaceutical compositions containing them |
-
2001
- 2001-08-29 FR FR0111201A patent/FR2829027A1/fr active Pending
-
2002
- 2002-08-27 AR ARP020103212A patent/AR036303A1/es not_active Application Discontinuation
- 2002-08-28 IL IL16055802A patent/IL160558A0/xx unknown
- 2002-08-28 EP EP02774886A patent/EP1423146A1/fr not_active Ceased
- 2002-08-28 WO PCT/FR2002/002945 patent/WO2003018060A1/fr not_active Ceased
- 2002-08-28 JP JP2003522575A patent/JP2005505539A/ja not_active Abandoned
- 2002-08-28 MX MXPA04001848A patent/MXPA04001848A/es unknown
- 2002-08-28 CA CA002458855A patent/CA2458855A1/en not_active Abandoned
-
2004
- 2004-02-25 US US10/786,483 patent/US7105504B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1423146A1 (fr) | 2004-06-02 |
| US7105504B2 (en) | 2006-09-12 |
| WO2003018060A1 (fr) | 2003-03-06 |
| AR036303A1 (es) | 2004-08-25 |
| FR2829027A1 (fr) | 2003-03-07 |
| JP2005505539A (ja) | 2005-02-24 |
| IL160558A0 (en) | 2004-07-25 |
| US20050107356A1 (en) | 2005-05-19 |
| CA2458855A1 (en) | 2003-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA04001645A (es) | Dispositivo de control de insectos que contiene coumaphos y diazinon para el tratamiento prolongado de animales. | |
| MXPA04001848A (es) | Asociacion de un antagonista del receptor cb1 y de un producto que activa la neurotransmision dopaminergica en el cerebro, las composiciones farmaceuticas que los contienen y su utilizacion para el tratamiento de la enfermedad de parkinson. | |
| AU2002337277A1 (en) | Compositions for the treatment of Parkinson's disease containing CB1 receptor antagonist and a product that activates dopaminergic neurotransmission in the brain | |
| MX9801305A (es) | Composicion de disolucion rapida oral para agonistas de dopamina. | |
| MY122392A (en) | Adamantane derivatives of use of p2x7 receptor antagonists, a process for their preparation, pharmaceutical compositions containing them and a process for preparing the pharmaceutical compositions | |
| BG64475B1 (bg) | Ципразидонови соли | |
| HUP0500107A3 (en) | 1-alkyl-1-azoniabicyclo[2.2.2.]octane carbamate derivatives, pharmaceutical compositions comprising thereof and their use as muscarinic receptor antagonists | |
| ZA200501082B (en) | Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof | |
| HUP0203836A3 (en) | 1,3-disubstituted pyrrololidines as alpha-2-adrenoceptor antagonists, process for their preparation and pharmaceutical compositions containing them and their use | |
| MXPA05009103A (es) | Derivados de 2-oxo-1,3,5-perhidrotriazapina utiles en el tratamiento de trastornos hiper-proliferativos, por angiogenesis, e inflamatorios. | |
| IL157093A0 (en) | 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin ii receptor antagonists | |
| TW200505483A (en) | New medicament compositions based on anticholinergically-effective compounds and β-mimetics | |
| NZ522326A (en) | Adenosine A2A receptor antagonists | |
| HUP0400246A3 (en) | 1,2,4-trioxolane antimalarial pharmaceutical compositions and process for their preparation and use | |
| BG105256A (en) | Muscarinic agonists and antagonists | |
| SI1545537T1 (sl) | Agonisti alfa-7 nikoninskega receptorja in statini v kombinaciji | |
| IL147977A0 (en) | Substituted 1,5-dihydropyrrol-2-on derivatives as nmda receptor antagonists for the treatment of pain | |
| MXPA04003298A (es) | Compuestos de piperidina como antagonistas muscarinicos. | |
| HUP0301228A3 (en) | 3-azabicyclo(3.1.0)hexane derivatives having opioid receptor affinity, process for their preparation and pharmaceutical compositions containing them | |
| HUP0303737A3 (en) | Indolinones, substituted in position 6, and their use as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | |
| HUP0401325A3 (en) | Isoxazolopyridinones useful in the treatment of parkinson's disease, process for their preparation and pharmaceutical compositions containing the compounds | |
| IL157065A0 (en) | 2h-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof | |
| MXPA04005552A (es) | Analogos de vitamina d. | |
| BG106548A (en) | Synergistic combinations of an nk1 receptor antagonist and a gaba structural analog | |
| BG102229A (en) | Endothelium receptor antagonists |